CY-09

Manufacturer	MedChem Express
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Amount	25 mg
Item no.	HY-103666-25mg
CASRN	1073612-91-5
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-immunoregulation
MolecularWeight	423.43
Clinical_Information	No Development Reported
Manufacturers Research_Area	Inflammation/Immunology
Solubility	DMSO : ≥ 150 mg/mL\|H2O : < 0.1 mg/mL
Manufacturers Target	NOD-like Receptor (NLR)
Isoform	NLRP3
Pathway	Immunology/Inflammation
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 25 mg

available

Request delivery time